“Virtonomy offers medical device developers the possibility of anatomical testing and optimization even before examinations take place in the animal laboratory to save valuable resources”, stated Prof. Dr. med. Hans-Dirk Düngen, SCIRENT’s CEO and Scientific Director.
“We are thrilled to leverage SCIRENT’s global talent and customer base and help them be among the first CRO to utilize our virtual patients,” stated Dr. Simon Sonntag, Virtonomy’s Chief Executive Officer. “Virtual patients not only bring faster, safer and better medical devices that can improve the lives of patients, but they also reduce the number of animals needed for testing along with risky human trials. We look forward to working together in this goal with SCIRENT.”
About SCIRENT: SCIRENT was founded in 2012 with the vision to help clients develop innovative medical drugs and devices for patients with cardiovascular diseases. Our dedicated team of experienced clinical and regulatory professionals can provide faster and more efficient service from our trial sites in Europe and North America. For more information about SCIRENT, please visit www.scirent.com.
About Virtonomy: Virtonomy is reducing costs and time-to-market of new medical devices from data-driven clinical trials using virtual patients. Our solution is based on an ever-expanding database that supports medical device manufacturers in the various phases of the product life cycle. From our headquarters in Munich, Germany, our team includes experts in medical engineering, image and data processing, visualization and clinical practice. For more information about Virtonomy, please visit www.virtonomy.io.